XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contracts with Customers

Summary of product revenue provision and allowance

​

​	​	​	​	​	​	​	​	​	​
​	​	​		​	​			Trade
​	​	Rebates and		​	Product		​	Allowances and
​	​	Incentives (1)		​	Returns (2)		​	Chargebacks (3)
Balance at December 31, 2022	​	$	156,937	​	$	73,554	​	$	22,058
Provision related to current period sales	​	​	92,871	​	​	10,166	​	​	34,921
Changes in estimate related to prior period sales	​	​	36	​	​	571	​	​	92
Credits/payments made	​	​	(122,852)	​	​	(10,381)	​	​	(32,563)
Balance at March 31, 2023	​	$	126,992	​	$	73,910	​	$	24,508

​

​	​	​	​	​	​	​	​	​	​
​		​		​	​			Trade
​	​	Rebates and		​	Product		​	Allowances and
​	​	Incentives (1)		​	Returns (2)		​	Chargebacks (3)
Balance at December 31, 2021	​	$	142,379	​	$	54,617	​	$	13,226
Acquired from BDSI	​	​	34,158	​	​	18,187	​	​	7,575
Provision related to current period sales	​	​	95,413	​	​	7,072	​	​	22,612
Changes in estimate related to prior period sales	​	​	(514)	​	​	—	​	​	(37)
Credits/payments made	​	​	(118,937)	​	​	(4,899)	​	​	(22,001)
Balance at March 31, 2022	​	$	152,499	​	$	74,977	​	$	21,375

​

(1) Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.

(2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.

(3) Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Consolidated Balance Sheets.

​

Schedule of disaggregation of revenue

​

​	​	​	​	​	​
​	Three Months Ended March 31,
​	2023		​	2022
Xtampza ER	$	47,869		$	31,518
Belbuca	​	44,212	​	​	3,310
Nucynta IR	​	27,899	​	​	29,335
Nucynta ER	​	21,136	​	​	19,263
Symproic	​	3,651	​	​	300
Other	​	—	​	​	25
Total product revenues, net	$	144,767	​	$	83,751

​

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration